[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562004":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":38,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"gastric cancer patients with peritoneal metastasis",null,"Initial diagnosis of gastric cancer with peritoneal metastases, excluding other distant metastases",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Jiajia Hu","CONTACT","0086-13524945287","jiajiahu@shsmu.edu.cn",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":28,"coordinates":29},"Point",[30,31],121.45806,31.22222,{"lat":31,"lon":30},[34],{"name":35,"role":15,"phone":36,"phoneExt":10,"email":37},"Zhongyin Yang","0086-13564877661","zyyang@shsmu.edu.cn",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hu Jiajia","Nuclear medicine","100562004","the-role-of-18f-fdgamp68ga-fapi-petct-in-the-assessment-of-conversion-therapy-efficacy-in-gastric-cancer-with-peritoneal-metastasis-100562004",false,"NCT06597526","The Role of 18F-FDG&68Ga-FAPI PET\u002FCT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.","The Role of 18F-FDG & 68Ga-FAPI PET\u002FCT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastatic","Inclusion Criteria:\n\n1. Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions\n2. Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction\n3. Patients voluntarily enrolled in this study by signing an informed consent form\n4. Age ≥ 18 years\n5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2,\n6. Expected life expectancy ≥ 3 months\n7. Adequate organ and bone marrow function\n8. Willingness to adhere to the study protocol and follow-up programme\n\nExclusion Criteria:\n\n1. Signs of distant metastases other than peritoneal metastases at enrolment\n2. Pregnant or breastfeeding women.\n3. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix\n4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease","ALL","18 Years",{"count":52,"type":53},30,"ESTIMATED","3 Years","OBSERVATIONAL","This study aims to investigate the value of 18F-FDG\\&68Ga-FAPI PET\u002FCT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.",[58,59],"Peritoneal Metastasis","Gastric Cancer",[61,62,63,64,65],"18F-FDG PET\u002FCT","68Ga-FAPI PET\u002FCT","gastric cancer","peritoneal metastases","conversion therapy","2024-09-13",{"date":68,"type":69},"2024-09-19","ACTUAL",{"date":71,"type":69},"2024-06-15",{"date":73,"type":53},"2029-05-31",{"name":5,"class":6},1]